Edwards Lifesciences Corp. (NYSE:EW)

Net sales exhibited a consistent upward trajectory from 2017 to 2021, increasing from US$ 3.44 billion to US$ 5.23 billion. The growth pattern was characterized by significant expansions in 2019 and 2021, with a notable period of relative stagnation observed in 2020, where revenue grew by less than 1%.

Transcatheter Aortic Valve Replacement (TAVR)

As the primary revenue driver, this segment showed steady and substantial growth, rising from US$ 2.02 billion in 2017 to US$ 3.42 billion in 2021. It consistently represents the largest portion of total net sales, underscoring its role as the core pillar of financial performance.

Transcatheter Mitral and Tricuspid Therapies

This segment demonstrated an exponential growth trend starting in 2019. From a modest base of US$ 3.4 million in 2017, revenues scaled rapidly to US$ 86 million by 2021, signaling a successful transition from early-stage market entry to a growth phase.

Surgical Structural Heart

Revenue in this category remained relatively stagnant over the five-year period, with values fluctuating between US$ 761 million and US$ 889 million. The lack of a strong upward trend suggests a mature segment with limited growth compared to the transcatheter portfolios.

Critical Care

A stable and positive growth trend is evident in the Critical Care segment, which increased from US$ 601 million in 2017 to US$ 834.9 million in 2021. This steady climb indicates consistent demand and contributes to the diversification of the total revenue mix.